



February 13, 2023
JCR Pharmaceuticals Co., Ltd.

Translation

Notice Regarding Support for Rare Disease Day 2023

Tuesday, February 28 is Rare Disease Day (hereinafter, "RDD"). RDD activities began in Sweden in 2008 intending to improve the quality of life of patients with rare and intractable diseases through better diagnoses and treatments. The number of patients with rare diseases is small for each disease, but it is estimated there are more than 6,000 identified rare diseases and 300 million people worldwide living with a rare disease (<https://www.rarediseaseday.org/>). JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") endorses the important mission of RDD activities and will continue to support RDD Japan 2023 this year, and we commit to raising awareness of rare diseases and creating a society in which it is easier for patients and their families to live.



Various events will be held as part of RDD Japan, based on the following theme: "RDD2023 in Japan: Speak, Spread, and Share – Our odyssey with RARE."

For details, please see the event's official website: <https://rddjapan.info/2023> (in Japanese).

In addition, JCR will display poster panels about lysosomal storage disorders, and mucopolysaccharidosis, in the FOOT TOWN on the 2nd floor of Tokyo Tower and on RDD Japan's website: <https://rddjapan.info/2023/panel/> (in Japanese).



What JCR can do
for rare diseases

To commemorate RDD, JCR promotes wearing official RDD badges to employees and conducts displaying posters in our office from January to February every year. This year is the 10th year that JCR has been starting our in-house RDD awareness-raising activities. In addition, we conduct more activities to foster awareness of RDD and encourage employees to participate in awareness-raising programs as members of a company engaged in rare disease by creating goods and posters with resolution for RDD.

JCR, as a specialty pharma in the rare disease arena, will continue to provide sustainable value to society in the spirit of the SDGs* of "no one will be left behind."

*Sustainable Development Goals

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases

worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, MPS II (Hunter syndrome), acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), Hunter syndrome, Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

###